Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and
course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of
the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with
wholebody MRI etc.